UK regulator bans Voy adverts over low‑testosterone claims

The Advertising Standards Authority has ruled that adverts by online healthcare provider Voy made misleading claims about at‑home test kits for low testosterone and has banned their publication. The regulator said the promotions overstated what the products could reliably determine.

The Advertising Standards Authority (ASA) has banned adverts placed by online healthcare firm Voy after finding that they made misleading claims relating to low testosterone.

The regulator concluded that the promotions for Voy's at‑home test kits suggested capabilities that were not supported by evidence, and that consumers could be misled about what the products could diagnose or determine. As a result, the adverts have been prohibited from further publication.

ASA rulings require advertisers to remove or amend promotional material that breaches the advertising code. In this case the watchdog said the content of the Voy adverts fell short of the standards set to protect consumers from inaccurate health claims.

The decision highlights growing regulatory scrutiny of direct‑to‑consumer health tests and online providers. Regulators and health professionals have repeatedly cautioned that certain conditions, including hormonal imbalances, often require clinical assessment and interpretation by qualified clinicians rather than reliance on self‑administered testing alone.

Voy, which offers a range of online health services and testing, will be expected to comply with the ASA's ruling and ensure future advertising does not repeat the breaches identified. The case adds to a series of recent enforcement actions aimed at ensuring health advertising is clear, accurate and substantiated.